Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Kura will see more combo data, while a new contender from Sumitomo emerges.
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
The company abandons TNG908, but is still all in on the troubled target.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
